GALECTIN THERAPEUTICS INC (GALT) stock intrinsic value fair value estimate & owner earnings analysis

Galectin Therapeutics is a clinical-stage biopharmaceutical company that has spent about twenty-five years and roughly $432 million in accumulated losses pursuing one compound, belapectin, and has never generated a dollar of product revenue. The case for the shares rests almost entirely on what happens next with that one compound, so that is where this analysis starts. Belapectin targets a real, underserved problem: patients with MASH-related compensated cirrhosis are at risk of developing esophageal varices (enlarged veins that can rupture and bleed), and no approved drug currently prevents that. The company's large, 357-patient global NAVIGATE trial finished in December 2024, and the main (composite) goal of the trial was not met with statistical significance - the trial failed on its primary objective. Inside the data, however, the 2 mg/kg dose group showed a statistically significant reduction in esophageal varices, and within the roughly 186 U.S. patients the reduction was 68%. That is a real, audited-trial finding, not a hope, and it is the one concrete asset the drug program has to build on. In December 2025 the company said it would pursue a follow-up meeting with the FDA to work out the design of a possible next pivotal trial built around that signal. As of this filing, that process is only in a preliminary stage: there is no agreed trial design, no committed budget, and no assurance a new trial will be attempted, let alone succeed. Because there is no approved product, no revenue, and no funded next trial today, there is nothing to build a growing cash-flow forecast on. Operating cash use was about $42 million in 2024 while the trial was still running, fell to about $24 million in 2025 as trial costs wound down, and fell further still in the first half of 2026 (an annualized rate of roughly $13 million) now that the company is essentially a lean shell awaiting the FDA's feedback. We treat 2025 - the first full year after the trial ended - as the more representative starting point than the trial-era years, since spending needed to run a 357-patient global trial is not representative of the company's ongoing cost base. The balance sheet is the other half of the story. At the end of 2025 the company had about $19.5 million of total assets against about $145.7 million of total liabilities - a stockholders' deficit of roughly $128 million, or over $1.90 for every share then outstanding - and the gap widened further through mid-2026. The overwhelming majority of that liability, over $130 million, is convertible debt owed to the company's chairman, Richard Uihlein, who has funded the company continuously since 2012 through a mix of equity and, increasingly, convertible loans that he can choose to convert into stock or roll forward rather than demand in cash. This related-party facility - not any product - is what has kept the company funded, and it has also driven heavy dilution: the share count grew from about 65 million at the end of 2025 to roughly 101 million by August 2026. The company's own filing is direct about the risk this creates: Mr. Uihlein has no obligation to keep funding the company beyond his existing commitments, and there is no assurance he will. Cash on hand plus the company's available credit line is, by management's own estimate, enough to fund operations only into April 2027. Putting this together, we see three distinct outcomes for the shares, not point estimates scaled up or down from one another: In the weak case, the FDA process does not produce a funded, agreed path to a new trial, Mr. Uihlein's support does not continue at the pace needed, and the company runs low on cash without a deal in hand. Given that liabilities already exceed assets by well over $100 million and that related-party debt and preferred stock stand ahead of common shares, common shareholders would be left with essentially nothing in that outcome - the shares are worth $0, not because the business is merely unprofitable, but because what it already owes is larger than what it owns. In our base case, Mr. Uihlein's thirteen-year record of continuing to fund the company (rather than forcing a default) continues, and the company survives as a going concern - but without a funded, de-risked drug program, because none exists today. Continued survival funded this way means continued heavy dilution with no offsetting revenue, so the residual value left for today's shareholders is very small - a few cents a share - reflecting little more than the option of staying alive long enough for the FDA discussion to produce something concrete. In our strong case, the FDA meeting leads to an agreed design for a new pivotal trial built around the 2 mg/kg signal, Mr. Uihlein's funding continues to support it, and the trial is completed and filed with the FDA within the next decade. We have kept this case deliberately modest: by the time any approval could arrive, the share count will have grown substantially from continued interim financing, and - because no comparable drug has ever been priced or sold for this exact use - we have not modeled specific peak sales, since there is no company-specific or market evidence to support a number. The value in this case reflects a company that has finally converted a real, evidenced scientific signal into a funded, credible late-stage program, not a commercial blockbuster. A few accounting choices matter here and are worth stating plainly. We built owner earnings from actual operating cash flow, adding back stock-based compensation as a real cost rather than ignoring it, and made no deduction for maintenance capital spending because the company owns essentially no manufacturing assets to maintain. We did not subtract the company's debt from the value of the business as a separate step - that debt, and the risk that its holder stops extending it, is instead reflected directly in the weak and base cases above. Because most of that debt converts into shares at roughly the market price in effect when it was drawn, converting it dilutes ownership more than it destroys per-share value on its own; the real damage to shareholders is the two decades of cash spent with no product to show for it yet. Given a company with no revenue, a failed primary trial endpoint, and a balance sheet already underwater by more than $100 million to a single lender, the margin-of-safety price is close to nothing today, and it applies only once an actual, funded FDA-agreed trial plan exists.